O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Neuroscience Long Term Care Specialist

Full-TimeUpdated on 10/23/2026
$116k - $166.8k+ Incentive opportunity
Junior
Bachelor's
Remote in USA+2 moreMore locations: New Orleans, LA, USA | Baton Rouge, LA, USA
RemoteUnited States (remote): Must reside within a commutable distance of 50 miles from Baton Rouge, Louisiana.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 2 years of pharmaceutical or medical device sales experience is required.
  • Demonstrate a comprehensive understanding of the long-term care environment, including regulatory requirements, operational challenges, and the specific needs of residents.
  • Identify and cultivate strategic relationships with key decision-makers within long-term care facilities, such as administrators, directors of nursing, and pharmacy managers.
  • Develop and execute tailored communication and sales strategies aligned with each long-term care facility's priorities.
  • Provide detailed, on-label product information in accordance with approved materials and regulatory standards.
  • Explain product access, including local market payer coverage, co-pay options, prior authorization requirements, formulary placement, and availability expectations.
  • Offer established guidance on patient care, including system protocols, standard-of-care guidelines, discharge protocols, and published expert opinions.
  • Use virtual or digital customer-engagement tools, including webinars, virtual meetings, digital newsletters, and interactive online platforms.
  • Use competitive data and business reports, including sales data and promotional budgets, to track progress and identify opportunities.
  • Understand territory and business conditions that affect sales results and establish near-term priorities for the territory business plan.
  • Respond compliantly to competitive threats and opportunities.
  • Educate office staff on payer guidelines and reimbursement procedures to increase product pull-through.
  • Use promotional materials effectively.
  • Maintain awareness of internal support-team resources and use them appropriately.
  • Apply market and industry knowledge to overcome objections and influence prescribing habits during customer calls.
  • Identify territory professional groups for networking and access to potential key opinion leaders.
  • Build relationships with office and practice personnel, focus conversations on patient health, follow through with accounts, and provide accurate information responsive to their needs.
  • Deliver balanced office calls and sales presentations using approved marketing materials and technical references, such as studies and package inserts, and demonstrate product and competitor knowledge.
  • Must reside within a commutable distance of 50 miles from Baton Rouge, Louisiana.
  • Ability to travel is required, including daily field travel by car.
  • Must communicate complex information effectively to healthcare providers and decision-makers.
  • Must conduct business in accordance with ethical standards, regulatory requirements, company policies, and guidance.
Responsibilities
  • Serve as the primary point of contact for long-term care accounts and healthcare providers.
  • Coordinate with local Neuroscience Specialists and cross-functional colleagues in Medical Affairs and Market Access under appropriate guardrails.
  • Coordinate speaker programs and organize local provider groups for discussions.
  • Share opportunities and feedback with the Area Business Lead, including local market insights to inform local strategy and team objectives.
  • Use knowledge of the long-term care environment to position solutions that add value to facilities.
  • Address product-access considerations so healthcare providers understand patient access and financial considerations.
  • Engage customers through virtual and digital tools to build relationships and support collaboration.
  • Develop territory business plans and sales priorities based on competitive data, sales results, and local market conditions.
  • Educate office staff on payer guidelines and reimbursement procedures.
  • Deliver sales presentations and provide accurate, approved product information to healthcare providers.
Desired Qualifications
  • Experience in pharmaceutical sales, healthcare management, or a related field is preferred.
  • Experience within long-term care and/or central nervous system specialties is highly advantageous.
  • At least 4 years of sales experience with healthcare providers, ideally representing multiple products, is preferred.
  • A thorough understanding of the long-term care environment, including its regulatory requirements, operational challenges, and residents' clinical needs, is preferred.
  • A proven ability to build and maintain strategic relationships with key stakeholders within long-term care facilities is preferred.
  • Ability to work effectively in an ambiguous environment undergoing transformation is preferred.
  • A proven track record in coaching, training, and mentoring peers or others is preferred.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Student Loan Assistance
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.